- RecruitingPHASE3
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
This study compares a new medicine called nemtabrutinib with existing treatments (ibrutinib or acalabrutinib) for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. The aim is to see if the new drug is as good or better.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
This study compares a new drug, pirtobrutinib, with existing approved treatments for people with a type of blood cancer called mantle cell lymphoma (MCL). It's for patients who have already had at least one treatment and are looking for other options.
For: Lymphoma, Mantle-CellUnited States · Australia · Austria - Active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL
This study looks at new drug combinations for people with newly diagnosed chronic lymphocytic leukemia (CLL). It compares these new treatments, acalabrutinib and venetoclax (with or without obinutuzumab), to standard chemotherapy to see which works best and is safest.
For: Chronic Lymphocytic LeukemiaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
This study is testing a new drug, surovatamig, for different types of B-cell blood cancers like leukaemia and lymphoma. Researchers want to see if it's safe and effective, either alone or with other cancer treatments.
For: Chronic Lymphocytic Leukaemia · Small Lymphocytic Lymphoma · Mantle-cell LymphomaUnited States · Australia · China - CompletedPhase I/II
The ACCEPT study
The ACCEPT study looks at a new treatment for diffuse large B-cell lymphoma (DLBCL). Researchers want to see if adding a targeted medicine called acalabrutinib to standard chemotherapy (R-CHOP) is safe and helps treat newly diagnosed patients better than usual care alone.
For: Diffuse large B-cell lymphomaUnited Kingdom · England - Active not recruitingPHASE3
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
This study tested new treatments for Chronic Lymphocytic Leukemia (CLL), a type of blood cancer, in people who had not been treated before. It compared different drug combinations to see which worked best to slow down or stop the cancer's progress.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
This study looks at new ways to treat Chronic Lymphocytic Leukemia (CLL), a type of blood cancer. Researchers are testing the safety of two drug combinations: venetoclax with obinutuzumab, or venetoclax with acalabrutinib. They want to see how well these treatments work and if they cause any side effects.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · France - Active not recruitingPHASE3
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
This study is looking at a new medicine called acalabrutinib. We want to see if adding it to standard treatment (bendamustine and rituximab, or BR) works better than standard treatment alone for people with a type of blood cancer called mantle cell lymphoma that hasn't been treated before.
For: Lymphoma, Mantle CellUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
This study compares two treatments, Acalabrutinib plus Venetoclax vs. Venetoclax plus Obinutuzumab, for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It's checking which combination works better and is safer.
For: Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaUnited States · Australia · Czechia - Active not recruitingPHASE3
A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312)
This study looks at a new drug called acalabrutinib combined with standard chemotherapy (R-CHOP) for a type of blood cancer called Diffuse Large B-Cell Lymphoma, in people who haven't had treatment before. We want to see if this combination works better and is safe.
For: Diffuse Large B-Cell LymphomaUnited States · Australia · Austria - RecruitingPHASE4
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
This study compares a drug called acalabrutinib with other standard treatments for people with chronic leukaemia and heart problems. It aims to see how safe and well acalabrutinib works in this group, particularly focusing on its effects on the heart.
For: Chronic Lymphocytic Leukaemia · Moderate to Severe Cardiac ImpairmentUnited States · Czechia · Italy - RecruitingPHASE3
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
This study compares two treatments for high-risk chronic lymphocytic leukaemia (CLL). One involves three drugs, and the other uses two. It aims to see if the three-drug combination can better prevent the disease from getting worse.
For: Chronic Lymphocytic LeukemiaGermany - Active not recruitingPHASE3
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
This study compares two medicines, Acalabrutinib and Ibrutinib, for people in the UK with a type of blood cancer called Chronic Lymphocytic Leukemia (CLL) that has been treated before. It wants to see which medicine works better at stopping the cancer from getting worse.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Belgium - Recruiting
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
This study looks back at how well a medicine called acalabrutinib worked for people in the UK with Chronic Lymphocytic Leukaemia (CLL) who took it first, as part of an early access programme. Researchers want to understand their experiences and treatment outcomes in real life.
For: Chronic Lymphocytic Leukemia, CLLUnited Kingdom - Active not recruitingPHASE1
A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
This study looks at a new combination of two medicines, Ceralasertib and Acalabrutinib, for people in the UK with a specific type of blood cancer called Chronic Lymphocytic Leukaemia (CLL). It wants to find out if this combination is safe and how well it works when other treatments haven't helped.
For: Chronic Lymphocytic LeukemiaPoland · United Kingdom - Active not recruitingPHASE2
Acalabrutinib and Rituximab in Previously Untreated Mantle Cell Lymphoma
This study is looking at a new combination of two drugs, acalabrutinib and rituximab, for older or less fit patients with a type of blood cancer called Mantle Cell Lymphoma. We want to see how safe and effective this treatment is.
For: Mantle Cell LymphomaUnited Kingdom - RecruitingPHASE1, PHASE2
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
This study is testing two medicines, KRT-232 and acalabrutinib, together for people with certain types of lymphoma or leukaemia that have come back or not responded to previous treatments. Researchers want to see if this combination is safe and works well.
For: Diffuse Large B Cell Lymphoma · Chronic Lymphocytic Leukemia · Non Hodgkin LymphomaUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
This study is looking at two new drug combinations for adults newly diagnosed with Chronic Lymphocytic Leukemia (CLL). It compares sonrotoclax plus zanubrutinib with venetoclax plus acalabrutinib to see which is more effective and safer for treating this type of blood cancer.
For: Chronic Lymphocytic LeukemiaUnited States · Australia · Brazil - Active not recruitingPHASE2
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
This study looks at a new combination of three chemotherapy-free drugs for people newly diagnosed with Mantle Cell Lymphoma. It aims to see if this treatment can clear the cancer and if some people can then stop treatment or use just one drug.
For: Mantle Cell Lymphoma (MCL)United States · Australia · Brazil - Active not recruitingPHASE2
A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome
This study is testing a new drug, acalabrutinib, alongside the usual treatment (CHOP-R) for Richter's Syndrome. It aims to see if this combination improves outcomes for people recently diagnosed with this aggressive blood cancer.
For: Richter SyndromeUnited Kingdom - Active not recruitingPHASE1, PHASE2
ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia
This study is testing a new medicine called acalabrutinib for people with certain types of blood cancer, like chronic lymphocytic leukaemia. It's looking to see if the medicine is safe and helps treat these conditions, especially when other treatments haven't worked.
For: Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma · Richter's SyndromeUnited States · Italy · United Kingdom